Part 1
A majority of patients with multiple sclerosis in Canada are advised to start treatment with a disease-modifying therapy, most commonly with an anti-CD20 treatment, according to the results of a recent survey on NeuroSens. The survey was conducted from 27 February-31 March 2025 and received 64 responses from MS neurologists and nurses. Read More
Click here to complete the interactive survey.
Once you submit your responses, you will be able to view all of your colleagues’ responses.
J.T. is a 42-year-old woman previously well except for frequent urinary tract infections, which included an episode of pyelonephritis with no known anatomical abnormality. She initially presented with two relapses about six months apart, a mild optic neuritis and a mild sensory myelopathy with excellent spontaneous recovery. Her EDSS score was 1.0. She was started on dimethyl fumarate. Read More
Webinar on recent adjunctive antiseizure medications with an emphasis on the use of cenobamate for focal epilepsies and fenfluramine for Dravet syndrome. Read More
The newly-published Discontinuing Disease-modifying Therapies in Stable Relapsing-onset Multiple Sclerosis (DOT-MS) is the second important trial to examine the feasibility of discontinuing disease-modifying therapy (DMT) in patients with multiple sclerosis (Coerver et al. JAMA Neurol 2025;82:123-131). Read More